Ann Michelle Cunningham - 09 Sep 2025 Form 4 Insider Report for Vistagen Therapeutics, Inc. (VTGN)

Reporting relationship: Director
Issuer ticker: VTGN
Reported as of: 09 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Sep 2025, 18:14:37 UTC
Prior SEC filing: 10 Sep 2024
Next SEC filing: 29 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Cynthia Anderson, Attorney-in-Fact

Key filing fact

Ann Michelle Cunningham filed Form 4 for Vistagen Therapeutics, Inc. (VTGN) on 11 Sep 2025.

Key facts

This page summarizes Ann Michelle Cunningham's Form 4 filing for Vistagen Therapeutics, Inc. (VTGN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Sep 2025, 18:14.

Change

Previous filing in this sequence was filed on 10 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001764572 Primary reporting owner

Cunningham Ann Michelle

Relationship: Director
Address: C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE, SOUTH SAN FRANCISCO
Signature: /s/ Cynthia Anderson, Attorney-in-Fact
Signature date: 11 Sep 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VTGN transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value: $0
Shares: +17,600
Change %
Price: $0.000000
Shares after: 17,600
Date: 09 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,600
Exercise price: $3.61
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant.